News and Information

Foreign start-ups eye China’s vast digital health care market, but finding the right revenue model holds the key to success

Start-ups such as Boston-based Biofourmis have partnered with local health care platforms like Jianke, giving the company access to its1.

Read More

25 Machine Learning Startups To Watch In 2019

Biofourmis is a fast-growing global digital health tech start-up that is reinventing remote patient monitoring by combining AI, machine learning…

Read More

AI-enabled monitoring, decision support platform Biofourmis raises $35M

Biofourmis, a Singapore-based startup pioneering a distinctly tech-based approach to the treatment of chronic conditions, has raised a $35 million Series B round for expansion.

The round was led by Sequoia India and MassMutual Ventures, the VC fund from Massachusetts Mutual Life Insurance Company. Other investors who put in include EDBI, the corporate investment arm of Singapore’s Economic Development Board, China-based healthcare platform Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate, a Singapore government initiative for deep tech startups. The round takes Biofourmis to $41.6 million raised to date, according to Crunchbase.

Read More

FDA Clears Biofourmis’ Software for ECG-based Arrhythmia Detection

The RhythmAnalytics platform can integrate with medical devices and other ECG management systems to detect arrhythmias.

Read More

Biofourmis CEO has Been Invited to Milken Institute’s Young Leader’s Circle

Our CEO and Co-Founder Kuldeep Singh Rajput was recently honoured with an invitation to join Milken Institute’s Young Leader’s Circle (continue)

Read More

Biofourmis’ RhythmAnalytics outperforms Cardiologist and State of Art Deep Learning Techniques for Arrhythmia Detection

We’re proud to say that our deep learning platform for ECG interpretation, RhythmAnalytics, outperforms a human analysis of an ECG with a high degree of accuracy! (continue)

Read More

Biofourmis CEO Entered into Forbes Asia 30 under 30 (Health Care)

Congratulations to our Founder and CEO Kuldeep Singh Rajput for making it into the Forbes Asia 30 Under 30 list for Healthcare and Science 2019! We’re excited to celebrate this well-deserved achievement as we continue on our mission to predict and prevent critical medical events before they happen!

Read More

BiovitalsHF™, a Prescription Software Uses Data Science to Augment Guideline-directed Use of Heart Failure Therapies

BOSTON, March 13, 2019 /PRNewswire/ — Biofourmis, a fast-growing digital therapeutics company focused on augmenting personalized care and therapies to empower patients with complex chronic conditions, today joined the American Heart Association’s Center for Health Technology & Innovation’s (Center) Innovators Network to deliver personalized software-based intervention including dose changes, heart failure education and insights to patients with heart failure.

Read More

Biofourmis Collaborates with Brigham and Women’s Hospital to Improve Patient Home Care

Biofourmis, a Singapore-based health analytics platform, has entered into a collaboration with Brigham and Women’s Hospital in Boston, US to co-develop improvements to their proprietary analytics engine, Biovitals™ for Brigham’s Home Hospital Programme.

Read More

Mundipharma and Biofourmis join forces to Revolutionise Pain Measurement and Management!

Leveraging on our biovitals™ analytics engine, painfocus™ uses advanced machine learning that combines multiple physiology biomarkers captured using wearable devices to calculate the presence and severity of pain, enabling clinicians to personalize treatment and manage their patients.

Read More

Making use of A.I. in health care

Kuldeep Singh Rajput, CEO of Biofourmis Group, explains how the start-up’s health platform looks at changes in a patient’s physiological data.

Read More

NSI Ventures Announces First Close of NSI Ventures II, L.P., Investment in Biofourmis and New Team Members

NSI is also pleased to announce that NSI Ventures II, L.P. has made its first investment in Biofourmis — a Singapore-based healthcare technology company using proprietary AI technology to prevent avoidable readmissions for post-acute cardiac patients. Aviva, a leading global insurance company also invested in Biofourmis this round.

Read More

Whether you are a healthcare provider,
payer or pharmaceutical,
biofourmis empowers you

Get In Touch